The plasma leak-to-response hypothesis: A working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 4, 2005, Pages

  Nakayama, Masaaki ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Encapsulating peritoneal sclerosis; EPS; High transporter; Plasma leak to response hypothesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CREATININE; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ARTICLE; AUSTRALIA; CREATININE BLOOD LEVEL; DIALYSATE LEVEL; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; JAPAN; LONG TERM CARE; MESOTHELIUM CELL; MICROCIRCULATION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEUM; PERITONEUM CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SCLEROSING PERITONITIS; VASCULAR DISEASE;

EID: 27744562298     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502504s10     Document Type: Article

References (22)

1. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S. Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
2. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
3. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
4. Nakayama M, Ikeda M, Katoh N, Hayakawa H, Numata M, Otsuka Y, et al. Long-standing high-transport membrane as a risk factor for EPS development after PD withdrawal: an analysis based on changes in peritoneal function during and after CAPD withdrawal (Japanese). Nippon Jinzo Gakkai Shi 2002; 44:396-401.
5. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18:131-4.
6. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis - Jikei experience 2002. Adv Perit Dial 2002; 18:144-8.
7. Nakayama M. The greater incidence of encapsulating peritoneal sclerosis is not the result of overdiagnosis. Perit Dial Int 2001; 21(Suppl3):S72-4.
8. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23:116-22.
9. Devuyst O. New insights in the molecular mechanisms regulating peritoneal permeability. Nephrol Dial Transplant 2002; 17:548-51.
10. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61:375-86.
11. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12:2146-57.
12. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
13. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12:1734-41.
14. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al., for the Peritoneal Biopsy Study Group. Morphological changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-9.
15. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
16. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; 14:21-8.
17. MacKenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFα secretion. J Am Soc Nephrol 1998; 9:1499-506.
18. Wieslander AP. Cytotoxicity of peritoneal dialysis fluids is related to glucose breakdown products. Nephrol Dial Transplant 1996; 11:958-9.
19. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2):S37-41.
20. Nakayama M, Yoshimura K, Maruyama Y, Numata M, Hosoya T, Izumi G. Possible involvement of cross-linking advanced glycation endproducts in long-term CAPD peritoneal degeneration. Nephrol Dial Transplant 2004; 19: 19-20.
21. Nakamura S, Tachikawa T, Tobita K, Miyazaki S, Sakai S, Morita T, et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003; 41(Suppl 1):S61-7.
22. Numata M, Nakayama M, Hosoya T, Hoff CM, Holmes CJ, Schalling M, et al. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clin Nephrol 2004; 62:455-60.